KYMR Stock Price, Kymera Therapeutics, . Quote, Chart

Market Summary

USD33.36+0.01

Delayed

0.03%

KYMR Stock Price

View Fullscreen

KYMR RSI Chart

KYMR Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-13.87

Price/Sales (Trailing)

25.94

Price/Free Cashflow

-14.85

KYMR Price/Sales (Trailing)

KYMR Profitability

Return on Equity

-37.21%

Return on Assets

-25.52%

Free Cashflow Yield

-6.74%

KYMR Fundamentals

KYMR Revenue

Revenue (TTM)

78.6M

Rev. Growth (Yr)

196.7%

Rev. Growth (Qtr)

912.8%

KYMR Earnings

Earnings (TTM)

-147.0M

Earnings Growth (Yr)

58.79%

Earnings Growth (Qtr)

72.82%

Breaking Down KYMR Revenue

Last 7 days

-1.8%

Last 30 days

-17.0%

Last 90 days

7.5%

Trailing 12 Months

6.2%

How does KYMR drawdown profile look like?

KYMR Financial Health

Current Ratio

4.73

KYMR Investor Care

Shares Dilution (1Y)

10.74%

Diluted EPS (TTM)

-2.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	46.7M	51.7M	46.8M	78.6M
2022	63.8M	56.7M	46.0M	46.8M
2021	49.3M	64.5M	70.3M	72.8M
2020	10.7M	18.5M	26.3M	34.0M
2019	0	0	0	2.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kymera Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	booth bruce	sold	-2,903,340	40.4567	-71,764	-
Mar 14, 2024	booth bruce	sold	-2,229,930	39.9779	-55,779	-
Mar 13, 2024	atlas venture fund x, l.p.	sold	-1,020,420	42.2273	-24,165	-
Mar 13, 2024	booth bruce	sold	-5,880,420	42.2277	-139,255	-
Mar 13, 2024	atlas venture fund x, l.p.	sold	-4,859,990	42.2278	-115,090	-
Mar 12, 2024	atlas venture fund x, l.p.	sold	-1,186,740	41.9773	-28,271	-
Mar 12, 2024	booth bruce	sold	-6,838,810	41.977	-162,918	-
Mar 12, 2024	atlas venture fund x, l.p.	sold	-5,652,070	41.977	-134,647	-
Mar 11, 2024	atlas venture fund x, l.p.	sold	-1,812,590	42.8487	-42,302	-
Mar 11, 2024	atlas venture fund x, l.p.	sold	-380,562	42.8465	-8,882	-

Which funds bought or sold KYMR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	unchanged	-	427	1,166	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	2,226	6,070	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	71.77	263,297	417,075	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-2.02	1,860,710	5,261,940	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	11.09	174,000	403,000	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	added	7.1	360,000	950,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.57	-85,000	53,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	230,795	508,309	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-2.00	102,562	289,922	0.01%
Apr 11, 2024	CONGRESS ASSET MANAGEMENT CO /MA	added	1.18	689,193	1,842,610	0.01%

Are Funds Buying or Selling KYMR?

Are funds buying KYMR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KYMR

No. of Funds

Unveiling Kymera Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	baker bros. advisors lp	9.8%	5,997,706	SC 13D
Feb 14, 2024	avoro capital advisors llc	6.8%	3,775,000	SC 13G/A
Feb 13, 2024	vanguard group inc	6.73%	3,997,564	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	10.1%	5,999,256	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	9.6%	5,340,414	SC 13G/A
Feb 09, 2024	atlas venture fund x, l.p.	8.4%	4,968,114	SC 13G/A
Feb 08, 2024	wellington management group llp	8.68%	4,815,558	SC 13G/A
Jan 29, 2024	blackrock inc.	6.4%	3,566,611	SC 13G/A
Jan 23, 2024	state street corp	3.41%	1,894,279	SC 13G/A
Jan 10, 2024	baker bros. advisors lp	10.8%	5,995,928	SC 13G/A

Recent SEC filings of Kymera Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 01, 2024	3	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	SC 13D	13D - Major Acquisition
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	4	Insider Trading

Peers (Alternatives to Kymera Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Kymera Therapeutics, Inc. News

Latest updates

Kymera Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	912.8%	47,885	4,728	16,513	9,466	16,139	9,551	11,514	9,622	15,275	20,336	18,519	18,702	12,785	14,533	3,288	3,428	2,189	950
Operating Expenses	8.0%	67,197	62,237	59,896	54,792	54,770	54,433	52,324	46,555	49,269	48,973	43,249	31,871	25,567	22,616	17,480	14,675	-	12,811
S&GA Expenses	0.8%	14,227	14,120	14,129	12,565	11,636	10,556	11,031	10,611	11,740	10,667	8,029	5,909	5,175	6,838	3,661	2,559	-	1,501
R&D Expenses	10.1%	52,970	48,117	45,767	42,227	43,134	43,877	41,293	35,944	37,529	38,306	35,220	25,962	20,392	15,778	13,819	12,116	-	11,310
Interest Expenses	27.0%	47.00	37.00	26.00	52.00	55.00	38.00	40.00	46.00	52.00	52.00	30.00	24.00	27.00	23.00	31.00	34.00	-	-
Net Income	72.8%	-14,368	-52,867	-38,799	-40,928	-34,865	-43,002	-40,257	-36,684	-33,900	-28,582	-24,660	-13,075	-12,685	-7,986	-13,989	-10,932	-	-11,420
Net Income Margin	47.7%	-1.87*	-3.57*	-3.05*	-3.41*	-3.31*	-3.35*	-2.46*	-1.94*	-1.38*	-1.12*	-0.90*	-0.97*	-	-	-	-	-	-
Free Cashflow	91.0%	-3,580	-39,725	-46,024	-47,977	-39,909	-35,515	-39,720	-40,777	-38,853	-37,566	-31,137	-22,987	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	4.2%	576	552	582	614	603	638	523	563	606	642	434	465	487	507	117
Current Assets	7.9%	405	376	385	412	419	494	403	431	451	544	365	341	302	297	93.00
Cash Equivalents	35.7%	110	81.00	52.00	50.00	68.00	156	77.00	34.00	48.00	157	85.00	53.00	31.00	55.00	76.00
Net PPE	33.2%	48.00	36.00	27.00	17.00	13.00	13.00	13.00	12.00	12.00	12.00	12.00	11.00	11.00	11.00	4.00
Liabilities	15.3%	181	157	147	152	113	126	125	134	146	159	176	189	203	213	82.00
Current Liabilities	35.7%	86.00	63.00	55.00	62.00	71.00	91.00	88.00	88.00	93.00	94.00	109	110	111	107	35.00
Shareholder's Equity	-0.1%	395	396	435	462	490	513	398	429	460	483	258	275	284	295	-
Retained Earnings	-2.8%	-530	-516	-463	-424	-383	-348	-305	-265	-228	-195	-166	-141	-128	-116	-76.46
Additional Paid-In Capital	1.3%	926	914	903	890	879	868	708	698	689	678	425	417	413	411	2.00
Shares Outstanding	5.3%	58.00	55.00	55.00	55.00	54.00	55.00	52.00	52.00	48.00	47.00	45.00	45.00	-	-	-
Float	-	-	-	1,013	-	-	-	792	-	-	-	1,688	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	125.4%	8,045	-31,647	-35,256	-43,968	-39,536	-34,269	-38,985	-40,295	-38,352	-37,260	-30,511	-22,823	-20,068	131,667	-11,412	-12,057	-	-
Share Based Compensation	-6.5%	10,898	11,655	11,180	9,385	8,909	9,076	9,622	7,873	8,678	7,396	5,726	3,172	1,827	2,328	664	371	-	-
Cashflow From Investing	-68.7%	18,952	60,511	35,839	24,584	-49,666	-37,481	81,803	25,863	-68,019	-136,862	60,723	44,323	-3,990	-334,321	-46,874	-37,403	-	-
Cashflow From Financing	1038.8%	1,934	-206	1,305	1,159	1,953	150,497	364	185	2,054	246,039	1,592	595	270	196,275	-403	93,120	-	-

KYMR Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaboration Revenue—from related party	$ 78,592	$ 46,826	$ 72,832
Revenue from Contract with Customer, Product and Service [Extensible List]	Collaboration Revenues From Related Party [Member]	Collaboration Revenues From Related Party [Member]	Collaboration Revenues From Related Party [Member]
Operating expenses:
Research and development	$ 189,081	$ 164,248	$ 137,017
General and administrative	55,041	43,834	36,345
Total operating expenses	244,122	208,082	173,362
Loss from operations	(165,530)	(161,256)	(100,530)
Other income (expense):
Interest and other income	18,764	6,624	488
Interest and other expense	(196)	(176)	(175)
Total other income	18,568	6,448	313
Net loss	(146,962)	(154,808)	(100,217)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities	4,397	(4,289)	(532)
Total comprehensive loss	(142,565)	(159,097)	(100,749)
Reconciliation of net loss to net loss attributable to common stockholders:
Net Income (Loss)	(146,962)	(154,808)	(100,217)
Net loss attributable to common stockholders	$ (146,962)	$ (154,808)	$ (100,217)
Net loss per share, basic	$ (2.52)	$ (2.87)	$ (2.09)
Net loss per share, diluted	$ (2.52)	$ (2.87)	$ (2.09)
Weighted average common shares outstanding, diluted	58,365,499	53,933,229	47,989,023
Weighted average common shares outstanding, basic	58,365,499	53,933,229	47,989,023

KYMR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 109,966	$ 68,395
Marketable securities (Note 4)	264,915	338,771
Accounts Receivable	15,000	0
Contract assets-due from related party	3,762	2,537
Prepaid expenses and other current assets	11,674	9,713
Total current assets	405,317	419,416
Marketable securities, non-current (Note 4)	61,434	152,328
Property and equipment, net (Note 6)	48,134	13,334
Right-of-use assets, operating leases	52,945	8,909
Other non-current assets	2,118	3,017
Restricted cash	5,811	6,130
Total assets	575,759	603,134
Current liabilities:
Accounts payable	7,075	4,335
Accrued expenses (Note 8)	33,864	27,502
Deferred revenue	37,883	35,260
Operating lease liabilities	5,068	2,535
Finance lease liabilities	1,277	1,408
Other current liabilities	524	303
Total current liabilities	85,691	71,343
Non-current liabilities
Deferred revenue, net of current portion	16,768	28,000
Operating lease liabilities, net of current portion	77,028	12,146
Finance lease liabilities, net of current portion	1,301	1,246
Other non-current liabilities	0	248
Total liabilities	180,788	112,983
Commitments and contingencies (Note 9)
Stockholders' equity:
Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2022 and 2021, 55,039,380 and 51,573,924 shares issued at December 31, 2022 and 2021, respectively; 55,039,380 and 51,536,181 shares outstanding at December 31, 2022 and 2021, respectively	6	6
Additional paid-in capital	926,269	878,884
Accumulated deficit	(530,752)	(383,790)
Accumulated other comprehensive loss	(552)	(4,949)
Total stockholders' equity	394,971	490,151
Total liabilities and stockholders' equity	$ 575,759	$ 603,134

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Nello Mainolfi M.D., Ph.D.
WEBSITE	kymeratx.com
INDUSTRY	Biotechnology
EMPLOYEES	181

Kymera Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Kymera Therapeutics, Inc.? What does KYMR stand for in stocks?

KYMR is the stock ticker symbol of Kymera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kymera Therapeutics, Inc. (KYMR)?

As of Fri Apr 26 2024, market cap of Kymera Therapeutics, Inc. is 2.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers. The fair value of Kymera Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kymera Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KYMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kymera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KYMR is over valued or under valued. Whether Kymera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kymera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KYMR.

What is Kymera Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, KYMR's PE ratio (Price to Earnings) is -13.87 and Price to Sales (PS) ratio is 25.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KYMR PE ratio will change depending on the future growth rate expectations of investors.